Compounds
AssigneeGlaxoSmithKline Intellectual Property Development Limited
InventorsZehong WAN, Yingxia Sang, Qing Zhang
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
Claims5
(S)-7-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy)-1,2-dimethyl-2,3-dihydroimidazo[1,2-c]pyrimidin-5(1H)-one
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a compound having a structure of
- or a pharmaceutically acceptable salt thereof,
- and one or more pharmaceutically acceptable excipients.
A method for treating neurodegeneration disease in a subject in need thereof comprising administering to the subject an effective amount of a compound having a structure of
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.